IP Library Granted Patent US 8,470,331
Granted Patent B2
US 8,470,331 · App. 10/181,684 · Granted Jun 25, 2013

Composition of antigen and glycolipid adjuvant for sublingual administration

Inventors: Alan W. Wheeler (Worthing, GB); Gary Elliott (Pacifica, CA); Christopher Cluff (Hamilton, MT)
Assignee: Allergy Therapeutics (UK) Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,470,331
App. No.
10/181,684
Granted
Jun 25, 2013
Kind
B2
Abstract

A method of producing a mucosal and systemic immune response in a mammal comprising administering sublingually an effective amount of a composition comprising at least one antigen and a glycolipid adjuvant to said mammal.

Claims (7)

1. A method for producing a mucosal and systemic immune response in a human or animal comprising administering an effective amount of a composition comprising at least one antigen and a TH-1 inducing adjuvant selected from a monophosphoryl lipid and a 3-de-O-acylated monophosphoryl lipid at a sublingual site of the human or animal, wherein the mucosal immune response is an IgA response and the systemic immune response is a serum IgG response, wherein the at least one antigen is derived from a virus, bacterium, prion, neoplasm, autoantigen, animal, plant, recombinant or synthetic material.

2. A method of producing an IgA immune response in a human or animal comprising administering an effective amount of a composition comprising at least one antigen and a TH-1 inducing adjuvant selected from a monophosphoryl lipid and a 3-de-O-acylated monophosphoryl lipid at a sublingual site of the human or animal, wherein the IgA immune response is a mucosal immune response at a site distal from the site of administration, wherein the at least one antigen is derived from a virus, bacterium, prion, neoplasm, autoantigen, animal, plant, recombinant or synthetic material.

3. The method of claim 1 , wherein the IgA immune response is distal from the sublingual site of administration of the composition.

4. The method of claim 1 , wherein the composition additionally comprises a sublingually administrable diluent, excipient, or carrier.

5. The method of claim 1 , wherein the composition comprises an aqueous solution, a gel, a capsule, a lozenge, or a tablet.

6. The method of claim 2 , wherein the composition additionally comprises a sublingually administrable diluent, excipient, or carrier.

7. The method of claim 2 , wherein the composition comprises an aqueous solution, a gel, a capsule, a lozenge, or a tablet.

Assignments (2)
CHANGE OF NAME Recorded Jun 13, 2010
From: ALLERGY THERAPEUTICS LIMITED
To: ALLERGY THERAPEUTICS (UK) LIMITED
Reel/Frame 024523/0809 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2002
From: WHEELER, ALAN; ELLIOTT, GARY; CLUFF, CHRISTOPHER WALLACE
To: ALLERGY THERAPEUTICS, LIMITED; CORIXA CORPORATION
Reel/Frame 013246/0384 →
Priority Claims (1)
GB 0000891.2 · Jan 14, 2000 · national
Continuity (1)
Related Publication 20030165512A1 · Sep 4, 2003